Recently Published CARRESS-HF Per Protocol Analysis Demonstrates Greater Fluid Reduction in Heart Failure Patients Using CHF Solutions’ Aquadex FlexFlow System

Posted on

EDEN PRAIRIE, Minn., April 10, 2018 (GLOBE NEWSWIRE) — A recently published study in the European Journal of Heart Failure highlighted a per protocol analysis of the CARRESS-HF study, which demonstrated that ultrafiltration with the Aquadex Flex Flow System by CHF Solutions, Inc. (Nasdaq:CHFS) was associated with a higher cumulative fluid loss (p=0.003), higher net fluid loss (p=0.001) and greater relative […]

Read More

CHF Solutions, Inc. Begins New Educational Program, “Facing the Facts about Fluid Overload” to Demonstrate the Need for Aquadex Therapy

Posted on

EDEN PRAIRIE, Minn., March 29, 2018 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS) announced today the launch of a new educational program, “Facing the Facts About Fluid Overload,” designed to inform providers about an alternative ultrafiltration therapy for heart failure patients with fluid overload who have failed diuretic therapy. “Intravenous diuretics have been the standard of care for […]

Read More

CHF Solutions, Inc. Announces Pricing of $18.0 Million Underwritten Public Offering

Posted on

EDEN PRAIRIE, Minn., Nov. 22, 2017 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (NASDAQ:CHFS) announced today the pricing of an underwritten public offering of Series F convertible preferred stock, together with warrants, for gross proceeds of $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions. The Series F preferred stock is convertible into shares of the […]

Read More

CHF Solutions, Inc. Announces Ultrafiltration Meta-Analysis Highlighting Significant Reduction in Heart Failure Readmissions at 90 Days

Posted on

EDEN PRAIRIE, Minn., Nov. 07, 2017 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (NASDAQ:CHFS) announced today that the Heart Failure Reviews released a comprehensive meta-analysis1 evaluating the role of ultrafiltration (UF) in reducing hospital readmissions in acute decompensated heart failure (ADHF) patients.  The positive results of this meta-analysis, which included CHF Solutions’ Aquadex FlewFlow® system, are consistent with previous publications that demonstrate […]

Read More

CHF Solutions’ Aquadex FlexFlow® Ultrafiltration System Receives FDA IDE Approval for Clinical Study for Pediatric Use

Posted on

EDEN PRAIRIE, Minn., June 29, 2017 (GLOBE NEWSWIRE) — CHF Solutions, Inc., (fka Sunshine Heart, Inc.) (NASDAQ:CHFS) announced today that researchers in the Stanford University School of Medicine’s Department of Pediatrics have received FDA Investigational Device Exemption (IDE) approval to conduct a clinical study to evaluate the safety and effectiveness of CHF Solutions’ Aquadex FlexFlow Aquapheresis System for diuretic-resistant fluid overload in children […]

Read More